BD Named to Bloomberg Gender-Equality Index for 4th Consecutive Year
Company’s Ongoing Commitment to Advance Workplace Equality Shows Progress in Female Leadership and Talent Pipeline
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to the 2023 Bloomberg Gender-Equality Index (GEI), marking the fourth consecutive year the company has been recognized on the index.
BD increased its scores across all pillars with noted improvements in external brand and female leadership and talent pipeline. This work demonstrates the company’s commitment and continued progress against its environmental, social and governance (ESG) goals for 2030 and beyond.
The 2023 Bloomberg Gender-Equality Index (GEI) is a modified market capitalization-weighted index developed to gauge the performance of public companies dedicated to reporting gender-related data. This reference index measures gender equality across five pillars: leadership and talent pipeline; equal pay and gender pay parity; inclusive culture; anti-sexual harassment policies; and external brand.
To learn more about the inclusion, diversity and equity systems, processes and tools that drive action and accountability at BD, read the 2022 Global Inclusion, Diversity and Equity Report.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
Media:
Investors:
Troy Kirkpatrick
Francesca DeMartino
VP, Public Relations
SVP, Head of Investor Relations
858.617.2361
201.847.5743
